Quantitative MRI for Patients With Sickle Cell Disease Undergoing Hematopoietic Cell Transplant
| Status: | Recruiting |
|---|---|
| Conditions: | Anemia |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | 5 - Any |
| Updated: | 5/6/2018 |
| Start Date: | May 3, 2018 |
| End Date: | August 2023 |
| Contact: | Connie Varner |
| Email: | convarne@med.umich.edu |
| Phone: | 7347643140 |
The primary purpose of this research is to determine if it is feasible to perform serial
magnetic resonance imaging (MRI) to evaluate the amount of bone marrow cells (also called
cellularity) and iron stores before and after bone marrow transplantation for severe sickle
cell disease.
magnetic resonance imaging (MRI) to evaluate the amount of bone marrow cells (also called
cellularity) and iron stores before and after bone marrow transplantation for severe sickle
cell disease.
Inclusion Criteria:
- Age ≥ 5 years.
- Diagnosis of SCD ([Hemoglobin SS (Hb-SS), Hemoglobin SC (Hb-SC) or Hemoglobin S-Beta
thalassemia (Hb-Sβ) genotype].
- Patient is a candidate for an allogeneic HCT.
- Subject or guardians have given informed consent.
Exclusion Criteria
- The need for general anesthesia for MRI.
- Subjects with implanted magnetic devices (e.g. pacemakers) that may malfunction or
move in the strong magnetic field.
- A subject who is pregnant.
- Previous HCT.
We found this trial at
1
site
500 S State St
Ann Arbor, Michigan 48109
Ann Arbor, Michigan 48109
(734) 764-1817
Principal Investigator: Ghada Abusin, MBBS
University of Michigan The University of Michigan was founded in 1817 as one of the...
Click here to add this to my saved trials
